SCHEMBL3898162

SCHEMBL3898162

OCC1(c2ccccc2)CCC=CCC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
DPP4 P27487 1/20 0.44
CCR1 P32246 1/20 0.40
HSD11B1 P28845 1/20 0.40
SLC6A4 P31645 5/20 0.39
SLC6A3 Q01959 4/20 0.39
SLC6A2 P23975 1/20 0.39
LMNA P02545 2/20 0.38
GAA P10253 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
OPRM1 P35372 3/20 0.37
OPRL1 P41146 3/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GRM2 Q14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1371770 0.87 MAOA (0.60) MAOAMAOBTAAR1DPP4CCR1
SCHEMBL7333210 0.83 DPP4 (0.57) MAOAMAOBTAAR1DPP4CCR1
SCHEMBL1152119 0.83 DPP4 (0.63) MAOAMAOBTAAR1DPP4SLC6A4
SCHEMBL2856019 0.81 DPP4 (0.61) MAOAMAOBTAAR1DPP4SLC6A4
Ammonia Solution, Strong SCHEMBL7260918 0.81 DPP4 (0.55) MAOAMAOBTAAR1DPP4CCR1
SCHEMBL5373534 0.78 MAOA (0.45) MAOAMAOBTAAR1DPP4CCR1
SCHEMBL6867538 0.78 MAOA (0.45) MAOAMAOBTAAR1DPP4CCR1
SCHEMBL1038938 0.78 TACR1 (0.56) MAOAMAOBTAAR1CCR1SLC6A4
SCHEMBL4792359 0.77 MAOA (0.46) MAOAMAOBTAAR1DPP4CCR1
SCHEMBL21283676 0.76 MAOA (0.44) MAOAMAOBTAAR1DPP4CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7494986-B2 Cycloalkylamine derivatives as NK-1/SSRI antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2009-02-24 US disclosed
US-7494986-B2 Cycloalkylamine derivatives as NK-1/SSRI antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2009-02-24 US disclosed
US-7494986-B2 Cycloalkylamine derivatives as NK-1/SSRI antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2009-02-24 US disclosed
US-20060019992-A1 Cycloalkylamine derivatives as NK-1/SSRI antagonists BRISTOL-MYERS SQUIBB COMPANY 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019992-A1 Cycloalkylamine derivatives as NK-1/SSRI antagonists SLC6A4, SLC6A2, TPH1 MAOA 557/4885MAOB 685/4885TAAR1 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.